Skip to main content
Equibles

Peter Lebowitz, M.D., Ph.D.

Board Member

BridgeBio Oncology Therapeutics, Inc. (BBOT)

Equibles does not estimate personal net worth.

About Peter Lebowitz, M.D., Ph.D.

Peter Lebowitz, M.D., Ph.D. is recorded as Board Member at BridgeBio Oncology Therapeutics, Inc. (BBOT) since June 16, 2026. BridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed June 22, 2026 that Peter Lebowitz, M.D., Ph.D. was appointed Class I director, effective June 16, 2026. BridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed March 26, 2026 that Peter Lebowitz, M.D., Ph.D. was appointed member of the Board, effective March 24, 2026. BridgeBio Oncology Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Oncology Therapeutics, Inc. includes Eli Wallace (CEO and Board Member), Pedro Beltran, Ph.D. (CEO and Board Member), Pedro J. Beltran, Ph.D. (CEO and Board Member) and 7 others.

“The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class I directors to hold office until the 2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.”
BridgeBio Oncology Therapeutics, Inc. Form 8-K, filed June 22, 2026 · Read the filing
“On March 24, 2026, the board of directors (the “Board”) of BridgeBio Oncology Therapeutics, Inc. (the “Company”) increased the size of the Board to nine (9) directors and, upon the recommendation from the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”) appointed Peter Lebowitz, M.D., Ph.D. as a member of the Board, with immediate effect to fill the vacancy created by the increase in Board size.”
BridgeBio Oncology Therapeutics, Inc. Form 8-K, filed March 26, 2026 · Read the filing

Affiliation history

Company network

Leadership on record at BridgeBio Oncology Therapeutics, Inc.

Recent activity